Robert Ca Robey

Address:

6302 Kenwood Ave APT B, Rosedale, MD 21237

VIN:

1HGFA16897L088910

Make:

HONDA

Model:

CIVIC

Year:

2007

US Patent:

6521635, Feb 18, 2003

Filed:

Jan 22, 2001

Appl. No.:

09/767594

Inventors:

Susan Bates - Bethesda MD
Robert Robey - Laurel MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 31435

US Classification:

514297, 514287, 514 33

Abstract:

This invention provides methods that are useful for inhibiting a MXR transporter in a cell overexpressing a MXR gene but not overexpressing a Pgp gene by contacting the cell with an acridine derivative. The invention also provides for a method of treating a mammal suffering from a cancer, which overexpressing a MXR gene but not overexpress a Pgp gene, by the co-administration of a chemotherapeutic and an acridine derivative.

US Patent:

8470888, Jun 25, 2013

Filed:

Dec 29, 2008

Appl. No.:

12/811144

Inventors:

Curtis J. Henrich - Rockville MD, US
Heidi R. Bokesch - Frederick MD, US
Laura K. Cartner - Middletown MD, US
Richard W. Fuller - Fairfield PA, US
Kirk R. Gustafson - Frederick MD, US
Kentaro Takada - Yokohama, JP
James B. McMahon - Frederick MD, US
Susan E. Bates - Bethesda MD, US
Robert W. Robey - Laurel MD, US
Suneet Shukla - Rockville MD, US
Suresh V. Ambudkar - Gaithersburg MD, US
Michael C. Dean - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 31/12
C07C 59/86

US Classification:

514679, 562459

Abstract:

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R, R, R, X, X, X, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.

US Patent:

20100267652, Oct 21, 2010

Filed:

Nov 5, 2008

Appl. No.:

12/742039

Inventors:

Curtis J. Henrich - Rockville MD, US
Heidi R. Bokesch - Frederick MD, US
Susan E. Bates - Bethesda MD, US
Robert W. Robey - Laurel MD, US
Suneet Shukla - Rockville MD, US
Suresh V. Ambudkar - Gaithersburg MD, US
Michael C. Dean - Frederick MD, US
James B. McMahon - Frederick MD, US

International Classification:

A61K 31/7042
A61K 31/4985
A61K 31/519
A61K 31/4439
A61K 31/40
A61K 31/295
A61P 35/04

US Classification:

514 26, 514250, 5142621, 514341, 514418, 514501

Abstract:

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.